Phenotypic differences of cryptococcus molecular types and their implications for virulence in a drosophila model of infection

Infection and Immunity

Volumn 82, Issue 7, 2014, Pages 3058-3065

  Thompson III, George R ^a,b   Albert, Nathaniel ^c   Hodge, Greg ^a   Wilson, Machelle D ^a   Sykes, Jane E ^b   Bays, Derek J ^a   Firacative, Carolina ^d   Meyer, Wieland ^d   Kontoyiannis, Dimitrios P ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; FLUCYTOSINE; HYDROGEN PEROXIDE; ITRACONAZOLE; MELANIN; POSACONAZOLE; VIRULENCE FACTOR; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DROSOPHILA MELANOGASTER; FRUIT FLY MODEL; FUNGAL VIRULENCE; FUNGUS ISOLATION; IN VITRO STUDY; IN VIVO STUDY; MELANOGENESIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; CRYPTOCOCCUS GATTII; DROSOPHILA MELANOGASTER; DRUG RESISTANCE, FUNGAL; GENE EXPRESSION REGULATION, BACTERIAL; MELANINS; VIRULENCE;

EID: 84903164089     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01805-14     Document Type: Article

References (47)

1. Sorrell TC. 2001. Cryptococcus neoformans variety gattii. Med. Mycol. 39:155-168. http://dx.doi.org/10.1080/mmy.39.2.155.168.
2. Ellis DH, Pfeiffer TJ. 1990. Natural habitat of Cryptococcus neoformans var. gattii. J. Clin. Microbiol. 28:1642-1644.
3. MacDougall L, Kidd SE, Galanis E, Mak S, Leslie MJ, Cieslak PR, Kronstad JW, Morshed MG, Bartlett KH. 2007. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg. Infect. Dis. 13:42-50. http://dx.doi.org/10.3201/eid1301.060827.
4. Byrnes EJ, III, Li W, Ren P, Lewit Y, Voelz K, Fraser JA, Dietrich FS, May RC, Chaturvedi S, Chaturvedi V, Heitman J. 2011. A diverse population of Cryptococcus gattii molecular type VGIII in southern Californian HIV/AIDS patients. PLoS Pathog. 7:e1002205. http://dx.doi.org/10.1371/journal.ppat.1002205.
5. Byrnes EJ, III, Li W, Lewit Y, Perfect JR, Carter DA, Cox GM, Heitman J. 2009. First reported case of Cryptococcus gattii in the Southeastern USA: implications for travel-associated acquisition of an emerging pathogen. PLoS One 4:e5851. http://dx.doi.org/10.1371/journal.pone.0005851.
6. Harris JR, Lockhart SR, Sondermeyer G, Vugia DJ, Crist MB, D'Angelo MT, Sellers B, Franco-Paredes C, Makvandi M, Smelser C, Greene J, Stanek D, Signs K, Nett RJ, Chiller T, Park BJ. 2013. Cryptococcus gattii infections in multiple states outside the US Pacific Northwest. Emerg. Infect. Dis. 19:1620-1626. http://dx.doi.org/10.3201/eid1910.130441.
7. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50:291-322. http://dx.doi.org/10.1086/649858.
8. Thompson GR, III, Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Graybill JR, Patterson TF. 2012. A murine model of Cryptococcus gattii meningoencephalitis. J. Antimicrob. Chemother. 67:1432-1438. http://dx.doi.org/10.1093/jac/dks060.
9. Kwon-Chung KJ, Bennett JE. 1984. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am. J. Epidemiol. 120: 123-130.
10. Fraser JA, Giles SS, Wenink EC, Geunes-Boyer SG, Wright JR, Diezmann S, Allen A, Stajich JE, Dietrich FS, Perfect JR, Heitman J. 2005. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 437:1360-1364. http://dx.doi.org/10.1038/nature04220.
11. Ngamskulrungroj P, Serena C, Gilgado F, Malik R, Meyer W. 2011. Global VGIIa isolates are of comparable virulence to the major fatal Cryptococcus gattii Vancouver Island outbreak genotype. Clin. Microbiol. Infect. 17:251-258. http://dx.doi.org/10.1111/j.1469-0691.2010.03222.x.
12. Thompson GR, III, Albert N, Hodge G, Wilson MD, Sykes JE, Bays DJ, Firacative C, Meyer W, Kontoyiannis DP. 2013. IDWeek: Jt. Meet. IDSA, SHEA, HIVMA, PIDS, San Francisco, CA, oral presentation 1824.
13. Ngamskulrungroj P, Sorrell TC, Chindamporn A, Chaiprasert A, Poonwan N, Meyer W. 2008. Association between fertility and molecular sub-type of global isolates of Cryptococcus gattii molecular type VGII. Med. Mycol. 46: 665-673. http://dx.doi.org/10.1080/13693780802210734.
14. Lin X, Litvintseva AP, Nielsen K, Patel S, Floyd A, Mitchell TG, Heitman J. 2007. alpha AD alpha hybrids of Cryptococcus neoformans: evidence of same-sex mating in nature and hybrid fitness. PLoS Genet. 3:1975-1990. http://dx.doi.org/10.1371/journal.pgen.0030186.
15. Lionakis MS, Lewis RE, May GS, Wiederhold NP, Albert ND, Halder G, Kontoyiannis DP. 2005. Toll-deficient Drosophila flies as a fast, highthroughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. J. Infect. Dis. 191:1188-1195. http://dx.doi.org/10.1086/428587.
16. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-3rd ed. CLSI document M27-A3. CLSI, Wayne, PA.
17. Thompson GR, III, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. 2009. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob. Agents Chemother. 53:309-311. http://dx.doi.org/10.1128/AAC.01216-08.
18. Chaturvedi V, Wong B, Newman SL. 1996. Oxidative killing of Cryptococcus neoformans by human neutrophils. Evidence that fungal mannitol protects by scavenging reactive oxygen intermediates. J. Immunol. 156: 3836-3840.
19. Pukkila-Worley R, Gerrald QD, Kraus PR, Boily MJ, Davis MJ, Giles SS, Cox GM, Heitman J, Alspaugh JA. 2005. Transcriptional network of multiple capsule and melanin genes governed by the Cryptococcus neoformans cyclic AMP cascade. Eukaryot. Cell 4:190-201. http://dx.doi.org/10.1128/EC.4.1.190-201.2005.
20. Zaragoza O, Casadevall A. 2004. Experimental modulation of capsule size in Cryptococcus neoformans. Biol. Proced. Online 6:10-15. http://dx.doi.org/10.1251/bpo68.
21. Byrnes EJ, III, Li W, Lewit Y, Ma H, Voelz K, Ren P, Carter DA, Chaturvedi V, Bildfell RJ, May RC, Heitman J. 2010. Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog. 6:e1000850. http://dx.doi.org/10.1371/journal.ppat.1000850.
22. Espinel-Ingroff A, Aller AI, Canton E, Castanon-Olivares LR, Chowdhary A, Cordoba S, Cuenca-Estrella M, Fothergill A, Fuller J, Govender N, Hagen F, Illnait-Zaragozi MT, Johnson E, Kidd S, Lass-Florl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, St-Germain G, Trilles L, Turnidge J. 2012. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob. Agents Chemother. 56:5898-5906. http://dx.doi.org/10.1128/AAC.01115-12.
23. Datta K, Rhee P, Byrnes E, III, Garcia-Effron G, Perlin DS, Staab JF, Marr KA. 2013. Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility. J. Clin. Microbiol. 51:3090-3093. http://dx.doi.org/10.1128/JCM.01190-13.
24. Marr KA. 2011. Cryptococcus gattii: the tip of the iceberg. Clin. Infect. Dis. 53:1196-1198. http://dx.doi.org/10.1093/cid/cir738.
25. Kunadharaju R, Choe U, Harris JR, Lockhart SR, Greene JN. 2013. Cryptococcus gattii, Florida, USA, 2011. Emerg. Infect. Dis. 19:519-521. http://dx.doi.org/10.3201/eid1903.121399.
26. Ngamskulrungroj P, Chang Y, Sionov E, Kwon-Chung KJ. 2012. The primary target organ of Cryptococcus gattii is different from that of Cryptococcus neoformans in a murine model. mBio 3:e00103-12. http://dx.doi.org/10.1128/mBio.00103-12.
27. Chen SC, Korman TM, Slavin MA, Marriott D, Byth K, Bak N, Currie BJ, Hajkowicz K, Heath CH, Kidd S, McBride WJ, Meyer W, Murray R, Playford EG, Sorrell TC, Australia and New Zealand Mycoses Interest Group (ANZMIG) Cryptococcus Study. 2013. Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. Clin. Infect. Dis. 57:543-551. http://dx.doi.org/10.1093/cid/cit341.
28. Schoffelen T, Illnait-Zaragozi MT, Joosten LA, Netea MG, Boekhout T, Meis JF, Sprong T. 2013. Cryptococcus gattii induces a cytokine pattern that is distinct from other cryptococcal species. PLoS One 8:e55579. http://dx.doi.org/10.1371/journal.pone.0055579.
29. Leongson K, Cousineau-Cote V, Goupil M, Aumont F, Senechal S, Gaboury L, Jolicoeur P, Kronstad JW, de Repentigny L. 2013. Altered immune response differentially enhances susceptibility to Cryptococcus neoformans and Cryptococcus gattii infection in mice expressing the HIV-1 transgene. Infect. Immun. 81:1100-1113. http://dx.doi.org/10.1128/IAI.01339-12.
30. Garcia-Solache MA, Izquierdo-Garcia D, Smith C, Bergman A, Casadevall A. 2013. Fungal virulence in a lepidopteran model is an emergent property with deterministic features. mBio 4:e00100-13. http://dx.doi.org/10.1128/mBio.00100-13.
31. Clancy CJ, Nguyen MH, Alandoerffer R, Cheng S, Iczkowski K, Richardson M, Graybill JR. 2006. Cryptococcus neoformans var. grubii isolates recovered from persons with AIDS demonstrate a wide range of virulence during murine meningoencephalitis that correlates with the expression of certain virulence factors. Microbiology 152:2247-2255. http://dx.doi.org/10.1099/mic.0.28798-0.
32. Ma H, Hagen F, Stekel DJ, Johnston SA, Sionov E, Falk R, Polacheck I, Boekhout T, May RC. 2009. The fatal fungal outbreak on Vancouver Island is characterized by enhanced intracellular parasitism driven by mitochondrial regulation. Proc. Natl. Acad. Sci. U. S. A. 106:12980-12985. http://dx.doi.org/10.1073/pnas.0902963106.
33. Nielsen K, De Obaldia AL, Heitman J. 2007. Cryptococcus neoformans mates on pigeon guano: implications for the realized ecological niche and globalization. Eukaryot. Cell 6:949-959. http://dx.doi.org/10.1128/EC.00097-07.
34. Liu OW, Chun CD, Chow ED, Chen C, Madhani HD, Noble SM. 2008. Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans. Cell 135:174-188. http://dx.doi.org/10.1016/j.cell.2008.07.046.
35. Jacobson ES, Compton GM. 1996. Discordant regulation of phenoloxidase and capsular polysaccharide in Cryptococcus neoformans. J. Med. Vet. Mycol. 34:289-291. http://dx.doi.org/10.1080/02681219680000491.
36. Nosanchuk JD, Rudolph J, Rosas AL, Casadevall A. 1999. Evidence that Cryptococcus neoformans is melanized in pigeon excreta: implications for pathogenesis. Infect. Immun. 67:5477-5479.
37. Wang Y, Aisen P, Casadevall A. 1995. Cryptococcus neoformans melanin and virulence: mechanism of action. Infect. Immun. 63:3131-3136.
38. Zaragoza O, Chrisman CJ, Castelli MV, Frases S, Cuenca-Estrella M, Rodriguez-Tudela JL, Casadevall A. 2008. Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell. Microbiol. 10:2043-2057. http://dx.doi.org/10.1111/j.1462-5822.2008.01186.x.
39. O'Meara TR, Alspaugh JA. 2012. The Cryptococcus neoformans capsule: a sword and a shield. Clin. Microbiol. Rev. 25:387-408. http://dx.doi.org/10.1128/CMR.00001-12.
40. Mitchell DH, Sorrell TC, Allworth AM, Heath CH, McGregor AR, Papanaoum K, Richards MJ, Gottlieb T. 1995. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin. Infect. Dis. 20:611-616. http://dx.doi.org/10.1093/clinids/20.3.611.
41. Winterbourn CC, Hampton MB, Livesey JH, Kettle AJ. 2006. Modeling the reactions of superoxide and myeloperoxidase in the neutrophil phagosome: implications for microbial killing. J. Biol. Chem. 281:39860-39869. http://dx.doi.org/10.1074/jbc.M605898200.
42. Lambou K, Lamarre C, Beau R, Dufour N, Latge JP. 2010. Functional analysis of the superoxide dismutase family in Aspergillus fumigatus. Mol. Microbiol. 75:910-923. http://dx.doi.org/10.1111/j.1365-2958.2009.07024.x.
43. Steenbergen JN, Shuman HA, Casadevall A. 2001. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc. Natl. Acad. Sci. U. S. A. 98:15245-15250. http://dx.doi.org/10.1073/pnas.261418798.
44. Gast CE, Basso LR, Jr, Bruzual I, Wong B. 2013. Azole resistance in Cryptococcus gattii from the Pacific Northwest: investigation of the role of ERG11. Antimicrob. Agents Chemother. 57:5478-5485. http://dx.doi.org/10.1128/AAC.02287-12.
45. Wellington M, Dolan K, Krysan DJ. 2009. Live Candida albicans suppresses production of reactive oxygen species in phagocytes. Infect. Immun. 77:405-413. http://dx.doi.org/10.1128/IAI.00860-08.
46. Eisenman HC, Frases S, Nicola AM, Rodrigues ML, Casadevall A. 2009. Vesicle-associated melanization in Cryptococcus neoformans. Microbiology 155:3860-3867. http://dx.doi.org/10.1099/mic.0.032854-0.
47. Rodrigues ML, Nakayasu ES, Oliveira DL, Nimrichter L, Nosanchuk JD, Almeida IC, Casadevall A. 2008. Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence. Eukaryot. Cell 7:58-67. http://dx.doi.org/10.1128/EC.00370-07.